Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade.
Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, Winter C, Malkova N, Sun F, Jaworski J, Best A, Pao L, Hebert A, Levit M, Protopopov A, Pollard J, Bahjat K, Wiederschain D, Sharma S. Greco R, et al. Among authors: pao l. Oncoimmunology. 2020 Sep 13;9(1):1811605. doi: 10.1080/2162402X.2020.1811605. Oncoimmunology. 2020. PMID: 33224628 Free PMC article.
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: pao l. Nature. 2022 Mar;603(7900):328-334. doi: 10.1038/s41586-022-04439-0. Epub 2022 Feb 23. Nature. 2022. PMID: 35197632
Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: pao l. Nature. 2022 Apr;604(7905):E13. doi: 10.1038/s41586-022-04652-x. Nature. 2022. PMID: 35332336 No abstract available.
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T. Mandel I, et al. Among authors: pao l. J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859. J Immunother Cancer. 2022. PMID: 36096532 Free PMC article.
Functional analysis of granzyme M and its role in immunity to infection.
Pao LI, Sumaria N, Kelly JM, van Dommelen S, Cretney E, Wallace ME, Anthony DA, Uldrich AP, Godfrey DI, Papadimitriou JM, Mullbacher A, Degli-Esposti MA, Smyth MJ. Pao LI, et al. J Immunol. 2005 Sep 1;175(5):3235-43. doi: 10.4049/jimmunol.175.5.3235. J Immunol. 2005. PMID: 16116214
107 results